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Abstract—Wound infection with antibiotic-resistant bacteria can 
extend a patients’ debility and increase the expense of treatment 
in the long term; therefore, careful management of patients with 
wound infections is necessary to avoid complications. The usage of 
antimicrobial agent is a major factor in resistance development. 
This study aims to understand the causes of wound infections, as 
well as the criteria for diagnosing them for more sensible antibiotic 
prescribing. Samples from 269 wound patients were collected, and 
cultured for bacterial growth. Gram stain technique, bacterial 
identification through VITEK 2 compact system was investigated 
in this study. Gram-negative bacteria (GNB) accounted for 59.15% 
of the total isolates, whereas pathogenic Gram-positive bacteria 
(GPB) accounted for 40.85% of total isolates. Escherichia coli 
and Pseudomonas aeruginosa are the dominant pathogenic GNB 
in wounds, whereas Staphylococcus aureus and Staphylococcus 
epidermidis are the dominant pathogenic GPB. P. aeruginosa 
showed 100% resistance to the majority of antibiotic tested, 
including Ampicillin, Amoxicillin/Clavulanic Acid, Aztreona, 
Ceftriaxone, and others. S. aureus and S. epidermidis are 100% 
resistant to Ampicillin, Ceftriaxone, and Cefotaxime. For more 
efficient antibiotic prescriptions, the causative microorganisms, 
and their current susceptibility patterns need to be mandated for 
testing before prescribing any antibiotics to patients. Prescriptions 
are frequently based solely on general information about the 
antibiotic’s function, rather than on individual response variation 
to the pathogen and the antibiotic. Particularly, when the common 
pathogens in this study show multidrug resistance in wounds.
Index Terms—Antibiotic resistance, Healing, Infection, Multi 
drug resistant, Pathogenic bacteria, Wound.
I. Introduction
Globally, infection with multidrug-resistance bacteria is 
the main contributing agent to nearly 700,000 deaths. This 
estimate is expected to rise to up to 10 million deaths by the 
year 2050 (Reale, et al., 2017). The main route of bacteria entry 
to the body is through open wounds. Among the four wound 
cleanliness classifications established by the US Centers for 
Disease Control and Prevention, clean, clean-contaminated, 
contaminated, and dirty-infected, the fourth class shows harm 
to skin, mucous membranes, and organs and can demonstrate 
microorganism infection and inflammation (Herman and 
Bordoni, 2021). Wound healing processes involve repair of 
the damaged tissue with the help of platelets, immune cells, 
fibroblasts, microvascular cells, and keratinocytes. The healing 
process is divided into four phases that coinciding with each 
other; coagulation, inflammation, proliferative (formation 
of granulation tissue), and formation (remodeling) phases 
(Chadwick and Ousey, 2019). Chronic non-healing wounds begin 
as minor damage, including those caused by insect bites, skin 
scratches, or deep skin penetration. Minor injuries usually heal 
in a few days or weeks, but in abnormal health conditions such 
as diabetes, the healing process takes much longer (Demidova-
Rice, et al., 2012). Chronic wounds have been classified into 
diabetic ulcers, pressure ulcers, and vascular ulcers. These types 
of chronic wounds are characterized by a longer inflammatory 
phase, infections, presence of biofilms, and unresponsiveness 
to skin healing stimuli (Frykberg and Banks, 2015). Infections 
with more than 105 live bacteria (or A-hemolytic streptococci) 
can cause harmful damage to the body. Viable bacteria or their 
toxins cause an inflammatory response, which can result in 
abscess, cellulites, and osteomyelitis. In addition to an increase 
in the production of Matrix metalloproteinases (MMPs) with 
the aid of the host’s immune cells. The MMP breaks down 
extracellular matrix and growth factors needed for tissue 
recovery in wounded regions. Bacteria are colonized in wounds 
form a biofilm. They are often associated with delayed wound 
healing (Demidova-Rice, et al., 2012). The bacterial capability 
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to endure antimicrobial agents has two components; antibiotic 
tolerance and antibiotic resistance. Tolerance is the bacterial 
ability to maintain their physical state in the presence of the 
antibiotic. These biofilms have a high tolerance to antimicrobial 
agents, but when the biofilm is disrupted the microbes become 
susceptible to antibiotic treatment (Chadwick and Ousey, 2019; 
Cooper, et al., 2014). Antibiotic resistance emerges as a result of 
the response to antibiotic exposure. It has developed naturally 
over billions of years as a microorganism’s successful survival 
strategy. However, bacteria have evolved antibiotic resistance 
mechanisms in <80 years since their introduction due to the 
overuse of antibiotics in human and animal health. Antibiotic 
resistance is one of the most serious risks to human health 
today. As a result, antimicrobial wound management remains a 
significant challenge that necessitates new approaches to combat 
microbes and their biofilms (Bowler, 2018; Daeschlein, 2013).
Gram-positive bacteria (GPB) are typically the first to 
penetrate the wound space; coagulase-negative staphylococci 
are the most common group obtained as commensals from 
the physiological milieu of unbroken skin in the wound’s 
vicinity. Days to weeks later, Gram-negative bacteria (GNB), 
primarily rods, penetrate the field and compete with surviving 
species, depending on the patient’s specific immunological 
habitat control. These germs usually come from sanitary 
barrier failures in everyday hospital hygiene, nutritional 
supply, and water. Other important microbial players in acute 
wounds are Pseudomonas aeruginosa and E. coli. Gram-
negative rods (Enterobacteriaceae) and P. aeruginosa are 
the most common species found in chronic wound biofilms, 
followed by Gram-positive cocci such as fecal streptococci 
(Enterococcus faecalis and Enterococcus faecium) and 
Staphylococcus aureus (Bowler, 2018; Negut, et al., 2018).
Because of the essential functional and esthetic role of this 
tissue, the treatment of wounds is a key research domain. When 
the skin’s barrier function is compromised, bacteria may quickly 
invade the underlying tissues, resulting in life-threatening 
infections. As a result, successful therapies for such pathological 
conditions are needed (Bjarnsholt, 2013). This study aims to 
describe the antibiotic resistance profile for bacterial pathogens 
present in infected wounds and make an assessment of the most 
suitable antibiotic with the best impact on wound healing.
II. Materials and Methods
A. Specimen Collection and Transport
Wound swaps were collected directly from patients 
attended Rizagary Teaching Hospital in Erbil city for the 
period between: January, 2014 and December, 2016. After the 
collection, 269 specimens were transported to laboratories of 
the microbiology department for analysis.
B. Bacterial Culture and Identification
After collection specimens were inoculated separately on: 
Blood, chocolate, and MacConkey agar. The inoculum was first 
smeared thoroughly over the surface of the solidified medium 
by sterilized loop. The loop was sterilized again and drawn-
out from the first site of inoculation into three parallel lines on 
fresh surfaces of the medium. Series of strokes were made in 
succession, with the inoculum derived from the most distal part of 
the immediately preceding strokes at each step. The plates were 
incubated overnight at 37°C. Number of colonies was counted 
and bacterial numbers were calculated per ml of specimen. For 
aerobic bacterial growth, colony characteristics and Gram’s 
staining were considered for their identification (Kumar, 2016). 
Classification of GPB and GNB was performed by following the 
VITEK® 2 compact system (bioMérieux S.A., France) using the 
following kits: VITEK®2 GN Reference 21341, VITEK®2 GP 
Reference 21342, and VITEK®2 AST-GN 82 Reference 413439.
C. Antibiotics
Antimicrobial sensitivity tests were performed using the VITEK® 
2 compact system (bioMérieux S.A., France) with the following 
kits: VITEK®2 AST-P580 Reference 22233, and VITEK®2 AST-
ST01 Reference 410028. The following antibiotics were covered in 
this study: AM-Ampicillin, AMC-Amoxicillin/Clavulanic Acid, AN-
Amikacin, ATM-Aztreonam, CAZ-Ceftazidime, CIP-Ciprofloxacin, 
CM-Clindamycin, CRO-Ceftriaxone, CTX-Cefotaxime, CZ-
Cefazolin, E-Erythromycin, ETP-Ertapenem, FA-Fusidic acid, 
FEP-Cefepime, FOS-Fosfomycin, FT-Nitrofurantoin, GM-
Gentamicin, IPM-Imipenem, LEV-Levofloxacin, LNZ-Linezolid, 
MEM-Meropenem, MNO-Minocycline, MUP-Mupirocin, MXF-
Moxifloxacin, OX1-Oxacillin, P-Benzylpenicillin, PEF-Pefloxacin, 
PIP-Piperacillin, RA-Rifampicin, SAM-Ampicillin/Sulbactam, 
SXT-Trimethoprim/Sulfamethoxazole, TEC-Teicoplanin, TE-
Tetracycline, TGC-Tigecycline, TIC-Ticarcillin, TM-Tobramycin, 
TZP-Piperacillin/Tazobactam, and VA-Vancomycin.
D. Data Analysis
Abundance, distribution, and drug sensitivity of all 
bacterial isolates were presented in percentile (%). When 
the percentile of sensitivity of a certain isolate was <30%, 
that isolate was considered to be resistant. For the collective 
antibiotic resistance in GPB and GNB, drugs were presented 
in a descending manner and only with a value ≥90% were 
considered to be highly resistant. For these calculations 
Microsoft Excel 2010 was used.
III. Results
A. Pathogenic Bacteria were Isolated in One Fourth of the 
Collected Samples
Pathogenic bacteria were recovered in 71 of the 269 
wound samples grown, accounting for 26.39% of the total 
samples. Non-pathogenic bacteria were found in 124 (46.1%) 
of the samples. Meanwhile, no bacterial growth was found in 
74 (27.51%) of the samples, (Table 1).
B. Gram-Negative Bacterial is the Dominant Type of 
Bacteria in Wounds
In wound isolates from 71 human individuals, pathogenic 
GNB were shown to be more prevalent than pathogenic GNB. 
GNB accounted for 42 (59.15%) of the total, while pathogenic 
GNB accounted for 29 (40.85%) of total isolates, (Table 2).
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C. E. coli and P. aeruginosa are the Dominant Pathogenic 
GNB in Wounds
E. coli and P. aeruginosa showed the higher growth in 
isolated bacteria representing 13 (30.95%) and 9 (21.43%) 
of total GNB identified, respectively, followed by Klebsiella 
pneumonia 5 (11.9%), Enterobacter cloacae 3 (7.14%), and 
Proteus mirabilis 3 (7.14%). Citrobacter koseri is the bacteria 
with the least dominance, accounting for only 1 (2.38%) of 
the total, (Table 3).
D. S. aureus is the Dominant Pathogenic GPB in 
Wounds
More than half of the isolated pathogenic GPB were S. 
aureus, followed by Staphylococcus epidermidis, which 
constituted one fourth of the total isolates. Staphylococcus 
haemolyticus and E. faecalis were found in only two colony 
isolates, as Streptococcus pneumoniae was the rarest. It was 
found only in one colony isolate, (Table 3).
E. Gram-Negative P. aeruginosa is 100% Resistant to Most 
of the Tested Antibiotics
E. coli showed 100% resistance to Pefloxacin and 
Piperacillin. As well as 92.31% resistance to Monocyline, 
84.62% resistance to Ampicillin, Amoxicillin/Clavulanic 
Acid, Aztreonam, and Ampicillin/Sulbactam, (Table 4). 
Whereas, the second dominant Gram-negative pathogen 
is P. aeruginosa showed 100% resistance to the majority 
of antibiotics tested, including Ampicillin, Amoxicillin/
Clavulanic Acid, Aztreona, Ceftriaxone, Cefazolin, 
Ertapenem, Nitrofurantoin, Minocycline, Pefloxacin, 
Piperacillin, Ampicillin/Sulbactam, Tigecycline, Ticarcillin, 
and Piperacillin/Tazobactam, (Table 5).
F. The Wound Dominant GPB are 100% resistant to 
Ampicillin, Ceftriaxone, and Cefotaxime
Antibiotic sensitivity test showed that S. aureus is 100% 
resistant to Ampicillin, Ceftriaxone, and Cefotaxime, and 
64.71% resistant to Ciprofloxacin. S. epidermidis is 100% 
resistant to Ampicillin, Ceftriaxone, and Cefotaxime. It 
also shows 85% resistance to Ciprofloxacin, Fusidic acid, 
and Quinupristin/Dalfopristin. Moreover, S. epidermidis is 
71.43% resistant to Erythromycin, and Teicoplanin, (Table 6).
G. Both GPB and GNB in Wounds are Resistant to 
Ampicillin
Collectively GPB were resistant to Ampicillin, Ceftriaxone, 
and Cefotaxime by 96.55%, followed by Ciprofloxacin 
and Quinupristin/Dalfopristin by 72.41% and 68.97%, 
respectively. Whereas, the bacteria were least resistant 
to Linezolid by 3.45%, and Fosfomycin, Moxifloxacin, 
Tigecycline, Benzylpenicillin by 6.89%. Collectively, GNB 
were resistant to Ampicillin by 92.86% and Minocycline by 
90.48%. Whereas, the least resistance was seen when using 
Amikacin by 33.33% and Cefepime by 40.48, (Table 7).
IV. Discussion
The over usage of antibiotics is a crucial factor in the 
development of resistance toward these drugs. Knowing the 
signs and symptoms of wound infections, as well as the 
causative organisms, and their current susceptibility trends 
are essential for pragmatic antibiotic prescribing (Filius 
and Gyssens, 2002). This study aimed to identify types of 
bacteria in wounds and their antibiotic susceptibility. Our 
results indicate that the dominant types of pathogenic bacteria 
in wounds are GNB E. coli and P. aeruginosa, accounting for 
30.95% and 21.43% of total GNB, respectively. In wounds, 
K. pneumoniae 11.9%, E. cloacae 7.14%, and P. mirabilis 
7.14% were found. The GNB with the least amount of 
dominance is C. koseri with only 2.38%.
Our result is similar to the finding of other research 
regarding predominance of GNB in wounds. Park, et al. 
(2017) reported that the majority (52%) of wound associated 
pathogens are of GNB. However, the commonalty of the 
species might show some differences for example in a 
research by Azzopardi, et al. (2014) found that the most 
prevalent Gram-negative-burn wound-pathogens were 
P. aeruginosa, K. pneumoniae, Acinetobacter baumannii, 
Enterobacter spp., Proteus spp., and E. coli (Azzopardi, 
et al., 2014; Azzopardi, et al., 2011; Park, et al., 2017).
S. aureus accounted for more than half of the pathogenic 
GPB identified, followed by S. epidermidis, which accounted 
Table I
Distribution of Bacterial Growth of Wound Swab Culture
Bacterial growth Number of growth (%)
No growth of bacteria 74 (27.51%)
No bacterial pathogen isolates 124 (46.1%)
Pathogenic bacteria isolates 71 (26.39%)
Table II
Distribution of Pathogenic Bacteria Isolated from Wound Swab 
Culture
Bacterial growth Number of growth (%)
GPB isolates 29 (40.85%)
GNB isolates 42 (59.15%)
Table III
Distribution of GNB and GPB Isolated from Wound Swab Culture
GNB isolates Number of 
isolates (%)
GPB isolates Number of isolates 
(%)
Escherichia coli 13 (30.95%) Staphylococcus 
aureus
17 (58.62%)
Pseudomonas aeruginosa 9 (21.43%) Staphylococcus 
epidermidis
7 (24.13%)
Klebsiella pneumonia 5 (11.9%) Staphylococcus 
haemolyticus
2 (6.9%)
Enterobacter cloacae 3 (7.14%) Enterococcus 
faecalis
2 (6.9%)
Proteus mirabilis 3 (7.14%) Streptococcus 
pneumoniae
1 (3.45%)
Acinetobacter baumannii 2 (4.76%) - -
Enterobacter aerogenes 2 (4.76%) - -
Klebsiella oxytoca 2 (4.76%) - -
Morganella morganii 2 (4.76%) - -
Citrobacter koseri 1 (2.38%) - -
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Table IV
Antimicrobial Agent’s Responses to the Isolated GNB
Agent Acinetobacter 
baumannii (2)
Citrobacter koseri (1) Enterobacter aerogenes (2) Enterobacter cloacae (3) Escherichia coli (13)
AM-Ampicillin R2 (100%) R1 (100%) R2 (100%) R3 (100%) S2 (15.38%) R11 (84.62%)
AMC-Amoxicillin/
Clavulanic Acid
R2 (100%) R1 (100%) R2 (100%) S2 (66.67%) R1 (33.33%) S2 (15.38%) R11 (84.62%)
AN-Amikacin R2 (100%) S1 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S7 (53.85%) R6 (46.15%)
ATM-Aztreonam R2 (100%) S1 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) S2 (15.38%) R11 (84.62%)
CAZ-Ceftazidime R2 (100%) S1 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S5 (38.46%) R8 (61.54%)
CIP-Ciprofloxacin R2 (100%) S1 (100%) S2 (100%) S3 (100%) S3 (23.08%) R10 (76.92%)
CRO-Ceftriaxone R2 (100%) S1 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) S3 (23.08%) R10 (76.92%)
CZ-Cefazolin R2 (100%) S1 (100%) R2 (100%) R3 (100%) S3 (23.08%) R10 (76.92%)
ETP-Ertapenem R2 (100%) S1 (100%) R2 (100%) S2 (66.67%) R1 (33.33%) S9 (69.23%) R4 (30.77%)
FEP-Cefepime R2 (100%) S1 (100%) S2 (100%) S3 (100%) S5 (38.46%) R8 (61.54%)
FT-Nitrofurantoin R2 (100%) R1 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) S5 (38.46%) R8 (61.54%)
GM-Gentamicin R2 (100%) S1 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) S9 (69.23%) R4 (30.77%)
IPM-Imipenem R2 (100%) S1 (100%) S2 (100%) S3 (100%) S12 (92.31%) R1 (7.69%)
LEV-Levofloxacin R2 (100%) S1 (100%) R2 (100%) S2 (66.67%) R1 (33.33%) S3 (23.08%) R10 (76.92%)
MEM-Meropenem R2 (100%) R1 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S7 (53.85%) R6 (46.15%)
MNO-Minocycline R2 (100%) R1 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) S1 (7.69%) R12 (92.31%)
PEF-Pefloxacin R2 (100%) R1 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) R13 (100%)
PIP-Piperacillin R2 (100%) R1 (100%) S2 (100%) R3 (100%) R13 (100%)
SAM-Ampicillin/
Sulbactam
S2 (100%) R1 (100%) R2 (100%) R3 (100%) S2 (15.38%) R11 (84.62%)
SXT-Trimethoprim/
Sulfamethoxazole
S2 (100%) S1 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) S7 (53.85%) R6 (46.15%)
TGC-Tigecycline R2 (100%) S1 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) S4 (30.77%) R9 (69.23%)
TIC-Ticarcillin R2 (100%) R1 (100%) S2 (100%) R3 (100%) R13 (100%)
TM-Tobramycin S1 (50%) R2 (50%) S1 (100%) S2 (100%) R3 (100%) S6 (46.15%) R7 (53.85%)
TZP-Piperacillin/
Tazobactam
R2 (100%) S1 (100%) S2 (100%) S3 (100%) S6 (46.15%) R7 (53.85%)
S: Sensitive, R: Resistant
Table V
Antimicrobial Agent’s Responses To The Isolated GNB




Proteus mirabilis (3) Pseudomonas aeruginosa 
(9)
AM-Ampicillin R2 (100%) R5 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
AMC-Amoxicillin/Clavulanic Acid R2 (100%) S1 (20%) R4 (80%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
AN-Amikacin S2 (100%) S3 (60%) R2 (40%) S2 (100%) S1 (33.33%) R2 (66.67%) S8 (88.89%) R1 (11.11%)
ATM-Aztreonam S2 (100%) R5 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
CAZ-Ceftazidime S2 (100%) R5 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S5 (55.56%) R4 (44.44%)
CIP-Ciprofloxacin S2 (100%) S1 (20%) R4 (80%) S2 (100%) S2 (66.67%) R1 (33.33%) S4 (44.44%) R5 (55.56%)
CRO-Ceftriaxone S2 (100%) R5 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
CZ-Cefazolin S2 (100%) R5 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
ETP-Ertapenem S2 (100%) S3 (60%) R2 (40%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
FEP-Cefepime S2 (100%) R5 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S8 (88.89%) R1 (11.11%)
FT-Nitrofurantoin R2 (100%) S1 (20%) R4 (80%) R2 (100%) R3 (100%) R9 (100%)
GM-Gentamicin S2 (100%) S1 (20%) R4 (80%) S (50%) R1 (50%) S1 (33.33%) R2 (66.67%) S6 (66.67%) R3 (33.33%
IPM-Imipenem S2 (100%) S3 (60%) R2 (40%) R2 (100%) R3 (100%) S8 (88.89%) R1 (11.11%)
LEV-Levofloxacin S2 (100%) R5 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) S4 (44.44%) R5 (55.56%)
MEM-Meropenem S2 (100%) S2 (40%) R3 (60%) S2 (100%) S1 (33.33%) R2 (66.67%) S8 (88.89%) R1 (11.11%)
MNO-Minocycline R2 (100%) R5 (100%) R2 (100%) R3 (100%) R9 (100%)
PEF-Pefloxacin R2 (100%) S1 (20%) R4 (80%) S2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
PIP-Piperacillin R2 (100%) R5 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
SAM-Ampicillin/Sulbactam S2 (100%) R5 (100%) R2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
SXT-Trimethoprim/Sulfamethoxazole S2 (100%) S1 (20%) R4 (80%) S1 (50%) R1 (50%) R3 (100%) S6 (66.67%) R3 (33.33%
TGC-Tigecycline S2 (100%) S2 (40%) R3 (60%) R2 (100%) R3 (100%) R9 (100%)
TIC-Ticarcillin S2 (100%) R5 (100%) S2 (100%) S1 (33.33%) R2 (66.67%) R9 (100%)
TM-Tobramycin S2 (100%) R5 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) S8 (88.89%) R1 (11.11%)
TZP-Piperacillin/Tazobactam S2 (100%) R5 (100%) S2 (100%) S2 (66.67%) R1 (33.33%) R9 (100%)
S: Sensitive, R: Resistant
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Table VI
Antimicrobial Agent’s Responses To The Isolated GPB
Agent Enterococcus 
faecalis (2)






AM-Ampicillin R2 (100%) R17 (100%) R7 (100%) R2 (100%) S1 (100%)
CIP-Ciprofloxacin R2 (100%) S6 (35.29%) R11 (64.71%) S1 (14.29%) R6 (85.71%) R2 (100%) S1 (100%)
CM-Clindamycin R2 (100%) S12 (70.59%) R5 (29.41%) S4 (57.14%) R3 (42.86%) R2 (100%) R1 (100%)
CRO-Ceftriaxone R2 (100%) R17 (100%) R7 (100%) R2 (100%) S1 (100%)
CTX-Cefotaxime R2 (100%) R17 (100%) R7 (100%) R2 (100%) S1 (100%)
E-Erythromycin R2 (100%) S12 (70.59%) R5 (29.41%) S2 (28.57%) R5 (71.43%) R2 (100%) S1 (100%)
FA-Fusidic acid R2 (100%) S10 (58.82%) R7 (41.18%) S1 (14.29%) R6 (85.71%) R2 (100%) S1 (100%)
FOS-Fosfomycin R2 (100%) S17 (100%) S7 (100%) S2 (100%) S1 (100%)
FT-Nitrofurantoin S2 (100%) S17 (100%) S7 (100%) S2 (100%) S1 (100%)
GM-Gentamicin R2 (100%) S16 (94.12%) R1 (5.88%) S7 (100%) S1 (50%) R1 (50%) S1 (100%)
LEV-Levofloxacin R2 (100%) S16 (94.12%) R1 (5.88%) S7 (100%) S1 (50%) R1 (50%) S1 (100%)
LNZ-Linezolid S1 (50%) R1 (50%) S17 (100%) S7 (100%) S2 (100%) S1 (100%)
MUP-Mupirocin R2 (100%) S9 (52.94%) R8 (47.06%) S5 (71.43%) R2 (28.57%) R2 (100%) R1 (100%)
MXF-Moxifloxacin R2 (100%) S17 (100%) S7 (100%) S2 (100%) S1 (100%)
OX1-Oxacillin R2 (100%) S11 (64.71%) R6 (35.29%) S7 (100%) S1 (50%) R1 (50%) R1 (100%)
P-Benzylpenicillin R2 (100%) S17 (100%) S7 (100%) S2 (100%) S1 (100%)
QDA-Quinupristin/Dalfopristin R2 (100%) S7 (41.18%) R10 (58.82%) S1 (14.29%) R6 (85.71%) S1 (50%) R1 (50%) R1 (100%)
RA-Rifampicin R2 (100%) S16 (94.12%) R1 (5.88%) S3 (42.86%) R4 (157.14%) R2 (100%) R1 (100%)
SXT-Trimethoprim/Sulfamethoxazole R2 (100%) S16 (94.12%) R1 (5.88%) S5 (71.43%) R2 (28.57%) S2 (100%) R1 (100%)
TE-Tetracycline R2 (100%) S9 (52.94%) R8 (47.06%) S3 (42.86%) R4 (157.14%) S1 (50%) R1 (50%) S1 (100%)
TEC-Teicoplanin S2 (100%) S10 (58.82%) R7 (41.18%) S2 (28.57%) R5 (71.43%) R2 (100%) R1 (100%)
TGC-Tigecycline S2 (100%) S15 (88.24%) R2 (11.76%) S7 (100%) S2 (100%) S1 (100%)
TM-Tobramycin R2 (100%) S9 (52.94%) R8 (47.06%) S6 (85.71%) R1 (14.29%) S1 (50%) R1 (50%) R1 (100%)
VA-Vancomycin S2 (100%) S15 (88.24%) R2 (11.76%) S3 (42.86%) R4 (57.14%) S1 (50%) R1 (50%) S1 (100%)
S: Sensitive, R: Resistant
Table VII
Pattern Of Antimicrobial Resistance Among Detected Bacteria
S. No. GPB GNB
Antibiotics % Resistance Antibiotics % Resistance
1. AM-Ampicillin 96.55 AM-Ampicillin 92.86
2. CRO-Ceftriaxone 96.55 MNO-Minocycline 90.48
3. CTX-Cefotaxime 96.55 PIP-Piperacillin 88.1
4. CIP-Ciprofloxacin 72.41 AMC-Amoxicillin/Clavulanic Acid 85.71
5. QDA-Quinupristin/Dalfopristin 68.97 CZ-Cefazolin 83.33
6. FA-Fusidic acid 58.62 FT-Nitrofurantoin 83.33
7. MUP-Mupirocin 51.72 PEF-Pefloxacin 83.33
8. TE-Tetracycline 51.72 SAM-Ampicillin/Sulbactam 83.33
9. TEC-Teicoplanin 51.72 TIC-Ticarcillin 83.33
10 E-Erythromycin 48.28 CRO-Ceftriaxone 80.95
11. CM-Clindamycin 44.83 TGC-Tigecycline 76.19
12. TM-Tobramycin 44.83 TZP-Piperacillin/Tazobactam 71.43
13. OX1-Oxacillin 34.48 LEV-Levofloxacin 69.05
14. RA-Rifampicin 34.48 ATM-Aztreona 64.29
15. VA-Vancomycin 24.14 ETP-Ertapenem 57.14
16. SXT-Trimethoprim/Sulfamethoxazole 20.69 CIP-Ciprofloxacin 52.38
17. GM-Gentamicin 13.79 CAZ-Ceftazidime 50
18. LEV-Levofloxacin 13.79 SXT-Trimethoprim/Sulfamethoxazole 45.24
19. FOS-Fosfomycin 6.89 TM-Tobramycin 45.24
20. MXF-Moxifloxacin 6.89 GM-Gentamicin 42.86
21. P-Benzylpenicillin 6.89 FEP-Cefepime 40.48
22. TGC-Tigecycline 6.89 MEM-Meropenem 38.1
23. LNZ-Linezolid 3.45 AN-Amikacin 33.33
24. - - IPM-Imipenem 26.19
for one-fourth of the total isolates. Only two colony isolates 
contained S. haemolyticus and E. faecalis, with S. pneumoniae 
being the least common. This finding is supported by other 
studies since S. aureus is reported to be the common GPB in 
wound patients (Mahat, et al., 2017; Guan, et al., 2021).
There seems to be variability in the diversity of bacterial 
culture in wounds. A study done by Bessa, et al. (2015) 
showed that the most common bacterial species detected was 
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S. aureus (37%), followed by P. aeruginosa (17%), P. mirabilis 
(10%), E. coli (6%), and Corynebacterium spp. Our results 
came in agreement with theirs regarding antibiotic sensitivity 
tests as they also reported that Vancomycin and Linezolid were 
effective against all GPB, and GNB revealed a significant level 
of resistance to the majority of antibiotics with Amikacin being 
the most effective against them (Bessa, et al., 2015).
In general, speaking, GPB were highly resistant 
toward each of Ampicillin, Ceftriaxone, and Cefotaxime. 
Meanwhile, they were highly sensitive to Fosfomycin, 
Moxifloxacin, P-Benzylpenicillin, Tigecycline, and Linezolid 
specifically. For being resistant by 100% to 19 (out of 24) 
drugs, E. faecalis was the most resistant recovered GPB. 
Since S. pneumoniae was sensitive by 100% toward 16 
(out of 24) drugs it was the most sensitive recovered GPB 
(Tables 6 and 7).
These results indicate that multidrug-resistant (MDR) 
bacteria were associated with the identified pathogens and 
may play a negative role in chronic wound infection. These 
findings come in agreement with previous studies of ours 
that confirmed the existence of MDR bacteria among patients 
identified with urinary tract and lower respiratory tract 
infections (Al-Naqshbandi, et al., 2019; Chawsheen, et al., 
2020; Abbas and Owaid, 2021).
IV. Conclusion
It is concluded from this research the importance of 
learning more about the causes of wound infections and 
the criteria for detecting them so that more appropriate 
antibiotics may be prescribed. GNB made up to two third 
of total bacterial isolates cultured from wounds. The most 
dominant pathogenic GNB were E. coli and P. aeruginosa. 
The most dominant pathogenic GNB isolated from wounds 
were S. aureus and S. epidermidis. The majority of 
antibiotics tested, including ampicillin, amoxicillin/clavulanic 
acid, Aztreona, Ceftriaxone, and others, exhibited 100% 
resistance. Ampicillin, Ceftriaxone, and Cefotaxime are 
completely ineffective against S. aureus and S. epidermidis. 
The pathogenic bacteria and their current susceptibility 
patterns must be enforced for testing before administering 
any antibiotics to patients for more efficient antibiotic 
prescriptions.
V. Recommendations
A significant number of MDR bacteria were recognized as 
the causal agents of wound infection in this study. Mandatory 
investigation of wound specimens, as well as antibiotic 
susceptibility testing, is recommended to guide physicians 
in pragmatic wound infection therapy, thereby reducing the 
propagation of resistant bacteria.
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